SCHEMBL7944780

SCHEMBL7944780

CN1C(=O)CC(C)(c2cc(NC(=O)c3cc4cc(Br)ccc4o3)ccn2)N=C1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
KMT2A Q03164 3/20 0.46
POLB P06746 3/20 0.46
BACE1 P56817 10/20 0.45
TP53 P04637 2/20 0.39
MEN1 O00255 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
NLRP3 Q96P20 1/20 0.39
MAPT P10636 5/20 0.39
RXFP1 Q9HBX9 3/20 0.39
KDM4E B2RXH2 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 1/20 0.38
HTT P42858 1/20 0.38
MMP2 P08253 1/20 0.37
MMP13 P45452 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
BLM P54132 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7940948 0.90 BACE1 (0.53) BACE1MMP2MMP13
SCHEMBL7941811 0.89 MAPT (0.50) NPC1RAB9AKMT2ABACE1TP53
SCHEMBL7946595 0.89 BACE1 (0.47) NPC1RAB9APOLBBACE1TP53
SCHEMBL7943456 0.86 BACE1 (0.49) NPC1RAB9AKMT2ABACE1MEN1
SCHEMBL7944285 0.86 BACE1 (0.60) NPC1RAB9AKMT2APOLBBACE1
SCHEMBL7939594 0.85 BACE1 (0.44) NPC1RAB9ABACE1TP53MAPT
SCHEMBL7933355 0.85 BACE1 (0.49) NPC1RAB9AKMT2APOLBBACE1
SCHEMBL7942132 0.84 BACE1 (0.52) NPC1RAB9APOLBBACE1TP53
SCHEMBL7943233 0.84 BACE1 (0.54) NPC1RAB9AKMT2APOLBBACE1
SCHEMBL12301705 0.83 BACE1 (0.60) BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 NPC1 431/4885RAB9A 1287/4885KMT2A 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.